BioTuesdays

Tag - CANF

Can-Fite

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

Can-Fite

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...

Can-Fite

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

Can-Fite

Can-Fite unveils clinical milestones for 2016

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016. “We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their...

Can-Fite

Can-Fite submits Phase 3 protocol for RA study

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions in several...

Can-Fite

Can-Fite gets patent in Japan for CF101

The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...